For sponsors seeking public reimbursement in Australia, submissions for diagnostic and investigative technologies present a fundamentally different challenge to therapeutic services. Under […]
Attend our Market Access Discussion Forum tailored for professionals in the pharmaceutical industry! This event provides a unique platform to network with […]
Pulse Economics is pleased to share that Oona Reardon, Managing Director, has been appointed as a member of the newly established Medicines Australia and AusBiotech Advanced Therapies […]
For medical device companies seeking reimbursement in the Australian private hospital system, inclusion on the Prescribed List (PL) remains critical. What has […]
On 6 November 2025, the US Centers for Medicare & Medicaid Services (CMS) announced the GENEROUS (GENErating cost Reductions fOr US Medicaid) […]
The Department of Health, Disability and Ageing has announced changes to their PBS Notice of Intent (NOI) process that will impact your […]
Attend our Market Access Forum tailored for professionals in the pharmaceutical industry! This event provides a unique platform to network with fellow […]
Exciting news! Pulse Economics is proud to be listed on the National AI Centre’s AI Directory, a platform showcasing Australia’s AI capabilities […]
Key challenges and opportunities shaping health technology assessment Next Tuesday’s ISPOR workshop brings together Australia’s leading HTA stakeholders: PBAC members, HTA Review […]
What we’re seeing We’ve been working with some remarkable Australian digital health companies lately. These are teams with genuinely impressive clinical evidence […]
